Zinzino AB

https://www.zinzino.com

Zinzino AB (publ.), headquartered in Gothenburg, Sweden, is a global health and wellness enterprise that has pioneered the rapidly growing market of test-based, personalized nutrition. Founded in 2005 and utilizing a highly scalable direct selling (social selling) distribution model, the company operates across over 100 markets worldwide. Guided by its core mission to "Inspire Change in Life," Zinzino empowers consumers to take charge of their preventative health by replacing guesswork with objective, scientifically backed data gathered from the comfort of their own homes.

The company's product ecosystem is fundamentally built around its proprietary at-home testing kits and corresponding premium nutritional supplements. Historically renowned for its BalanceTest—a precise dried blood spot test that measures essential fatty acid levels to help users correct global Omega-3 deficiencies—Zinzino continuously pushes the boundaries of wellness technology. Most notably, the company recently introduced a revolutionary Gut Health Test, which it internally dubbed its "moon landing in test-based nutrition." This highly innovative kit completely replaces traditional, messy stool samples with a simple, sustainable finger-prick blood test to accurately measure key metabolites linked to gut and immune function. To complement its diagnostics, Zinzino offers targeted interventions ranging from Omega-3 blends and the skin-nourishing Collagen Boozt to Multify, a specialized, kid-friendly multivitamin.

Currently guided by CEO Dag Bergheim Pettersen, Zinzino is navigating a period of explosive, record-breaking global growth. Following the celebration of its 20th anniversary, the company delivered a monumental 2025 financial year, generating SEK 3.34 billion in revenue—an astonishing 51% year-over-year increase—alongside record-high EBITDA margins. Moving through early 2026, Zinzino has aggressively expanded its North American distribution network by executing a string of major acquisitions, including the assets of Texas-based Zurvita and the prominent wellness brand It Works!. This dominant commercial momentum was further validated in April 2026 when Direct Selling News (DSN) honored Zinzino with a prestigious Bravo Award for industry excellence and officially elevated the company to #20 on the DSN Global 100 list, cementing its status as a premier force in the global personalized nutrition space.

Latest updates

Zinzino Ascends Direct Selling Ranks, Claims Top 20 Global Position

Event summary

  • Zinzino has been awarded a DSN Bravo Award by Direct Selling News.
  • The company now ranks #20 on the DSN Global 100 list of largest direct selling companies.
  • The DSN Bravo Awards recognize achievement across growth, leadership, innovation, and industry impact.
  • Zinzino attributes its success to test-based personalized nutrition, digital tools, and a partner-driven distribution model.

The big picture

Zinzino's ascent within the direct selling industry, evidenced by the Bravo Award and Top 20 Global ranking, highlights the continued appeal of personalized nutrition and the power of network-based distribution models. While the direct selling sector has faced challenges, Zinzino’s focus on scientific validation and digital tools appears to be driving growth. The company’s position within the Global 100 suggests a significant, albeit niche, player in a multi-billion dollar market.

What we're watching

Partner Dependency
The company's reliance on a partner-driven distribution model presents a potential vulnerability if partner engagement or recruitment slows, impacting revenue growth.
Competitive Landscape
The direct selling industry faces increasing scrutiny and competition from e-commerce platforms and traditional retail channels, requiring Zinzino to continually innovate its product offerings and distribution strategies.
Regulatory Risk
As a direct selling company operating globally, Zinzino is exposed to evolving regulatory frameworks concerning health claims, data privacy, and distributor compensation, which could impact operational costs and market access.

Zinzino Board Member Resignation Adds to Governance Scrutiny

Event summary

  • Anna Frick resigned from the Zinzino AB board, effective immediately.
  • Frick was initially elected to the board on May 20, 2021.
  • The board now comprises Chairman Hans Jacobsson, Staffan Hillberg, Ingela Nordenhav, and Pierre Mårtensson.
  • The stated reason for Frick’s departure is personal.

The big picture

The resignation of a board member, even with a stated personal reason, can trigger investor scrutiny, especially in companies with recent governance challenges or a history of operational volatility. Zinzino, operating in the competitive health and wellness sector, faces constant pressure to demonstrate stability and transparency. While a single departure is not inherently alarming, it warrants close observation for any underlying issues or potential impact on strategic execution.

What we're watching

Succession Planning
The speed at which Zinzino replaces Frick will signal the board's preparedness for unexpected departures and its commitment to maintaining a diverse skillset.
Governance Risk
Further board turnover, particularly if occurring within a short timeframe, could raise concerns about overall governance stability and internal cohesion.
Strategic Alignment
How the remaining board members, particularly the Chairman, navigate the company’s strategic direction without Frick’s input will reveal potential shifts in priorities or approaches.

Zinzino Sales Surge Masks Regional Disparities in Q1 2026

Event summary

  • Zinzino group revenue increased 26% year-over-year to SEK 915.4 million in Q1 2026.
  • March sales reached SEK 342.2 million, a 29% increase compared to the previous year.
  • Faun Pharma's external sales declined slightly, falling to SEK 6.6 million from SEK 7.1 million.
  • North America and South America demonstrated exceptionally strong growth, with increases of 71% and 413% respectively.
  • East Europe experienced a 13% revenue decrease, contrasting with the overall positive trend.

The big picture

Zinzino's robust Q1 2026 results highlight the company's continued success in leveraging the direct sales model across diverse geographic markets. However, the uneven regional performance and the contrasting trajectory of Faun Pharma suggest a more nuanced strategic landscape. The company's ability to address these disparities and maintain momentum will be crucial for long-term value creation, particularly as competition in the health and wellness sector intensifies.

What we're watching

Regional Performance
The significant divergence in growth rates between regions, particularly the decline in East Europe, warrants further investigation to understand underlying market conditions and Zinzino’s strategic response.
Faun Pharma Impact
The continued modest decline in Faun Pharma's external sales, despite overall group growth, suggests potential integration challenges or strategic realignment that could impact future profitability.
Sustainability
The rapid growth in South America, while impressive, raises questions about the sustainability of this pace and potential risks associated with scaling operations in a developing market.

Zinzino Issues Shares to Settle Acquisition-Related Claims

Event summary

  • Zinzino issued 401,965 new B shares to S&M Nano-Biotechnology S.A DE C.V. in exchange for claims related to the acquisition of Sanki assets and subsidiaries on November 8, 2025.
  • A further 69,621 new B shares were issued to Bodē Pro, settling claims related to the acquisition of Bodē Pro on September 12, 2025.
  • The total share issuance amounts to 471,586 shares, increasing the total share count to 38,634,966 and diluting existing shareholders by 1.22%.
  • The share capital increase is relatively minor, totaling SEK 47,159, bringing the total share capital to SEK 3,863,497.

The big picture

Zinzino's strategy of acquiring smaller brands to expand its product portfolio and geographic reach appears to be continuing, but the use of directed share issues to settle acquisition-related claims is a notable financing method. This approach, while common, can be viewed negatively by investors if it becomes a recurring pattern, potentially signaling difficulties in generating sufficient cash flow to fund acquisitions organically. The relatively small size of the share capital increase suggests these acquisitions are not transformative for the overall company size.

What we're watching

Integration Risk
The success of Zinzino's strategy hinges on the effective integration of Sanki and Bodē Pro, and these share settlements suggest ongoing financial adjustments related to those acquisitions.
Financial Health
Continued reliance on share-based settlements to manage acquisition costs could signal underlying financial pressures or difficulty in securing traditional financing.
Shareholder Sentiment
While the dilution is relatively small, repeated share issuances may erode investor confidence and impact the company's valuation if not clearly justified by operational improvements.

Zinzino Sales Surge Masks Regional Weakness in February

Event summary

  • Zinzino group revenue increased by 32% year-over-year in February 2026, reaching SEK 286.3 million.
  • Faun Pharma’s external sales rose by 24% to SEK 5.2 million.
  • Year-to-date (January-February) revenue increased by 26% to SEK 568.6 million.
  • Nordic and East European regions experienced revenue declines of 9% and 10% respectively in February.
  • North and South American regions saw significant growth, with increases of 108% and 200% respectively.

The big picture

Zinzino’s strong overall revenue growth masks underlying regional vulnerabilities. The company’s reliance on emerging markets for a significant portion of its gains exposes it to currency fluctuations, political instability, and evolving consumer preferences. While the Faun Pharma acquisition appears to be contributing positively, its strategic fit and long-term value remain to be fully evaluated.

What we're watching

Regional Disparities
The contrasting performance between high-growth regions (North/South America) and declining regions (Nordics/East Europe) warrants further investigation into localized market conditions and Zinzino’s regional strategies.
Faun Pharma Integration
While Faun Pharma's sales are growing, the overall contribution remains small; the long-term strategic value of this subsidiary and its integration with Zinzino’s core business needs to be assessed.
Sustainability
Continued reliance on rapid growth in emerging markets like South America carries inherent risks; Zinzino must diversify its geographic footprint to ensure sustainable, long-term revenue generation.

Zinzino Triples Down on Acquisitions, Rewards Shareholders with Dividend Hike

Event summary

  • Zinzino reported full-year 2025 revenue of SEK 3.34 billion, a 51% increase year-over-year.
  • The company’s EBITDA margin improved to 13.3% in 2025, up from 11.4% the previous year, driven by stronger gross profit and synergies from acquisitions.
  • Zinzino acquired a 35% stake in Xion International Group to secure omega-3 supply and acquired the assets of Sanki to expand distribution in the Americas.
  • The Board proposes a dividend of SEK 6.00 per share, a 50% increase from the previous year, totaling SEK 217.9 million.
  • Following the reporting date, Zinzino acquired It Works! to bolster distribution in North America and Europe.

The big picture

Zinzino’s rapid growth and shareholder returns are fueled by a strategy of aggressive acquisitions and expansion into new markets. The company’s focus on direct sales and nutritional supplements places it within a competitive landscape, and its reliance on acquisitions carries integration risk. The move to secure omega-3 supply through Xion International Group signals a broader trend towards supply chain resilience within the health and wellness sector.

What we're watching

Acquisition Integration
The success of Zinzino’s aggressive acquisition strategy hinges on effectively integrating It Works! and Sanki, which could be challenging given the diverse business models.
Sustainability
The investment in Xion International Group to secure omega-3 supply demonstrates a focus on sustainability, but the viability of algae bioreactor production at scale remains to be seen.
Distribution Scale
Zinzino’s reliance on direct sales and acquisitions to drive growth exposes it to potential saturation and regulatory scrutiny in key markets.

Zinzino Expands Latin American Footprint with Peru Launch

Event summary

  • Zinzino is launching operations in Peru on February 10, 2026.
  • Peru has generated approximately SEK 1.5 million in monthly sales for Zinzino through its global web shop.
  • The expansion leverages Zinzino’s existing Latin American infrastructure and experience.
  • CEO Dag Bergheim Pettersen cites Peru as a 'natural next step' in Latin American growth.

The big picture

Zinzino’s expansion into Peru underscores the ongoing trend of direct selling companies targeting emerging markets with flexible income opportunities. The company's reliance on digital commerce and community-driven sales aligns with the evolving consumer landscape in Latin America, but the success of this strategy will depend on navigating local regulatory environments and competition. This move represents a continued effort to diversify revenue streams beyond established European markets.

What we're watching

Market Adoption
The success of Zinzino’s model in Peru will hinge on Partner recruitment and retention rates, which are often a key indicator of direct selling business viability.
Regional Synergies
How effectively Zinzino can leverage its existing Latin American infrastructure to support the Peruvian launch will determine the speed and efficiency of market penetration.
Competitive Landscape
The presence of established direct selling companies and local nutrition brands in Peru could create headwinds for Zinzino’s market share gains.

Zinzino Sales Surge Driven by North American and South American Growth

Event summary

  • Zinzino group revenue increased by 20% year-over-year to SEK 281.2 million in January 2026.
  • Sales in Zinzino's core markets rose by 20%, reaching SEK 274.1 million.
  • Faun Pharma's external sales grew by 51% to SEK 7.1 million.
  • North American sales experienced a dramatic 94% increase, reaching SEK 41.3 million.
  • South American sales saw a massive 344% increase, reaching SEK 4.0 million.

The big picture

Zinzino's preliminary January 2026 sales report demonstrates a significant acceleration in growth, particularly in North and South America. This expansion, coupled with the performance of Faun Pharma, suggests a successful geographic diversification strategy. However, the contrasting performance in East Europe highlights potential vulnerabilities within the company's regional market penetration, requiring careful monitoring and strategic adjustments to maintain overall growth momentum.

What we're watching

Regional Sustainability
The significant growth in South America, while impressive, warrants scrutiny to determine if this is a sustainable trend or a temporary spike, and whether it is indicative of broader market penetration or a localized phenomenon.
East Europe Performance
The 14% decline in East European sales is a concerning outlier against the broader positive trend and requires investigation to understand the underlying causes and potential corrective actions.
North American Scaling
Zinzino must carefully manage its rapid expansion in North America to avoid operational bottlenecks and ensure the quality of its distribution network can support the increased volume.

Zinzino Acquires It Works! to Expand North American, European Reach

Event summary

  • Zinzino has merged with US-based direct sales company It Works! in an all-share transaction.
  • The acquisition cost USD 30 million, settled through the issuance of 1,843,840 Zinzino B-shares.
  • An additional USD 4 million purchase price, also in shares, is contingent on future sales performance over five years.
  • Zinzino anticipates the merger will generate over USD 60 million in additional revenue in 2026.
  • The transaction resulted in a dilution of approximately 4.83% of Zinzino's total shares and 2.24% of its total votes.

The big picture

Zinzino's acquisition of It Works! signals a continued strategy of consolidating market share within the direct sales sector, particularly in North America and Europe. This all-share deal, while avoiding immediate cash outlay, introduces significant dilution for existing shareholders and underscores the company's reliance on equity financing for growth. The move reflects a broader trend of established players acquiring smaller, specialized brands to expand distribution and product offerings in the increasingly competitive health and wellness market.

What we're watching

Integration Risk
The success of the merger hinges on Zinzino's ability to effectively integrate It Works!' operations and distributor networks, which could be complicated by differing sales approaches and cultures.
Share Dilution
Continued reliance on share issuance to fund acquisitions will likely put downward pressure on Zinzino's share price, particularly if future sales targets are not met.
Sales Performance
The contingent USD 4 million payment tied to future sales performance will be a key indicator of the merger's long-term value and Zinzino's ability to leverage It Works!' existing customer base.

Zinzino Sales Surge Masks Faun Pharma Decline

Event summary

  • Zinzino group revenue increased 51% year-over-year to SEK 3,344.5 million for full-year 2025.
  • Q4 2025 revenue grew 46% to SEK 1,042.4 million, with December sales up 35% to SEK 334.4 million.
  • Faun Pharma’s external sales significantly decreased, falling 51% to SEK 50.4 million for the year.
  • Revenue growth was geographically uneven, with North America and Asia-Pacific exhibiting the strongest expansion (172% and 254% respectively).

The big picture

Zinzino’s impressive revenue growth highlights the effectiveness of its direct sales model and geographic expansion strategy. However, the significant decline in Faun Pharma’s performance introduces a potential strategic overhang and could signal a broader portfolio review. The company's ability to maintain its high growth trajectory will depend on navigating regional market dynamics and addressing the performance gap within its subsidiaries.

What we're watching

Subsidiary Risk
The stark contrast in performance between Zinzino and Faun Pharma raises questions about the strategic fit and potential for further divestiture or restructuring within the group.
Regional Sustainability
While North America and Asia-Pacific demonstrate impressive growth, the sustainability of these rates, particularly in North America, needs to be assessed against potential market saturation and increased competition.
Growth Dependency
Zinzino's reliance on rapid geographic expansion to drive overall revenue growth creates a vulnerability if expansion slows or encounters regulatory or logistical challenges in new markets.
CID: 135